- Reported transaction lines
- 8
- Buy lines
- 0
- Sell lines
- 6
Filing activity by month
Original filing lines in up to 12 months with activity.
- 2026-118
Frequently disclosed stocks
Disclosure history
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source |
|---|---|---|---|---|---|---|
| BALL KRISTINE M Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | Exercise or conversionFiling detailsSEC transaction code M Stock Option (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 53426 · The option vests as to 1/4 of the underlying shares on May 7, 2025 and as to 1/48 of the underlying shares monthly from May 7, 2025. | 2026-11-12 | 2026-11-13 | 18,000 shares/units | SEC 4 |
| BALL KRISTINE M Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 0 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.97 to $107.00, inclusive. | 2026-11-12 | 2026-11-13 | ≈ $21,397.00 200 shares/units | SEC 4 |
| BALL KRISTINE M Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 200 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.76 to $106.46, inclusive. | 2026-11-12 | 2026-11-13 | ≈ $265,130.00 2,500 shares/units | SEC 4 |
| BALL KRISTINE M Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 2700 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.76 to $105.75, inclusive. | 2026-11-12 | 2026-11-13 | ≈ $1,133,706.29 10,765 shares/units | SEC 4 |
| BALL KRISTINE M Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 13465 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.69 to $104.65, inclusive. | 2026-11-12 | 2026-11-13 | ≈ $212,386.73 2,039 shares/units | SEC 4 |
| BALL KRISTINE M Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 15504 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.66 to $103.65, inclusive. | 2026-11-12 | 2026-11-13 | ≈ $134,021.16 1,300 shares/units | SEC 4 |
| BALL KRISTINE M Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 16804 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.62 to $102.61, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4. | 2026-11-12 | 2026-11-13 | ≈ $122,107.65 1,196 shares/units | SEC 4 |
| BALL KRISTINE M Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 18000 | 2026-11-12 | 2026-11-13 | 18,000 shares/units | SEC 4 |
Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.